Cytokinetics (CYTK) vs Dr. Reddy's Laboratories (RDY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cytokinetics (CYTK) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 1.6% versus a loss of 12.5%. Over five years, CYTK leads with a +65.7% price change compared with -7.1% for RDY. Dr. Reddy's Laboratories is the larger company by market cap ($10.22 billion vs $8.56 billion), about 1.2 times the size, while Cytokinetics is growing revenue faster (+376.6% vs +13.8%).
Dr. Reddy's Laboratories pays a dividend yielding 65.23%, while Cytokinetics does not currently pay one. Dr. Reddy's Laboratories converts more of its revenue into profit, with a net margin of 17.4% versus -891.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYTK | RDY |
|---|---|---|
| Share price | $61.60 | $12.27 |
| Market cap | $8.56B | $10.22B |
| 1-day change | +0.79% | -0.04% |
| YTD return | -3.81% | -12.61% |
| 1-year return | +1.58% | -12.54% |
| 5-year return | +65.68% | -7.06% |
| P/E ratio (TTM) | — | 27.88 |
| Forward P/E | — | 19.04 |
| EPS (TTM) | $-7.22 | $0.44 |
| Dividend yield | 0.00% | 65.23% |
| Annual dividend | $0.00 | $8.00 |
| Revenue (latest FY) | $88.04M | $3.81B |
| Revenue growth (YoY) | +376.56% | +13.76% |
| Net income (latest FY) | $-784.96M | $663.00M |
| Gross margin | — | 58.51% |
| Operating margin | -695.44% | 22.09% |
| Net margin | -891.60% | 17.40% |
| 52-week high | $88.31 | $15.67 |
| 52-week low | $54.30 | $11.36 |
| Distance from 52-week high | -30.25% | -21.73% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +78.41% | +7.79% |
| Average volume | 1.96M | 2.89M |
| Shares outstanding | 139.02M | 832.99M |
| Employees | 673 | 27,527 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYTK has outperformed RDY by 14.1 percentage points over the past year.
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (65.23% vs 0.00%).
- Dr. Reddy's Laboratories is more profitable, keeping 17.4 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
- Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs +13.76%).
About Cytokinetics
CYTK stock →Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
CYTK vs RDY FAQ
Which is bigger, Cytokinetics or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories (RDY) is larger, with a market capitalization of $10.22B compared with $8.56B for Cytokinetics (CYTK).
Which stock has performed better over the past year, CYTK or RDY?
CYTK returned +1.58% over the past 12 months, compared with -12.54% for RDY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Cytokinetics or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories pays a dividend yielding 65.23%, while Cytokinetics does not currently pay a regular dividend.
Are Cytokinetics and Dr. Reddy's Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.